Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy

J Antimicrob Chemother. 2016 Aug;71(8):2359-61. doi: 10.1093/jac/dkw147. Epub 2016 May 4.

Authors

A Borghetti¹, G Baldin², A Ciccullo², R Gagliardini², A D'Avino², A Mondi², N Ciccarelli², S Lamonica², I Fanti², E Trecarichi², M Fabbiani³, R Cauda², A De Luca⁴, S Di Giambenedetto²

Affiliations

¹ Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy al.bor86@gmail.com.
² Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy.
³ Division of Infectious Diseases, Department of Internal Medicine, University of Milan-Bicocca, Monza, Italy.
⁴ Division of Infectious Diseases, Department of Medical Biotechnologies, University of Siena and Siena University Hospital, Siena, Italy.

PMID: 27147306
DOI: 10.1093/jac/dkw147

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adult
Anti-HIV Agents / administration & dosage
Anti-HIV Agents / adverse effects
Anti-HIV Agents / therapeutic use*
Drug Therapy, Combination / adverse effects
Drug Therapy, Combination / methods
Female
HIV Infections / drug therapy*
HIV Infections / virology
HIV-1 / drug effects
Heterocyclic Compounds, 3-Ring / administration & dosage
Heterocyclic Compounds, 3-Ring / adverse effects
Heterocyclic Compounds, 3-Ring / therapeutic use*
Humans
Lamivudine / administration & dosage
Lamivudine / adverse effects
Lamivudine / therapeutic use*
Male
Middle Aged
Oxazines
Piperazines
Pyridones
Retrospective Studies
Viral Load / drug effects*

Substances

Anti-HIV Agents
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
Lamivudine
dolutegravir